Header_01 Header_02 Header_03 Header_04
    Home     Academic Profile     Publications     Contact Us     Image Gallery
Navigation
»   Home
»   Lectures
Contact Us
Address:
Islamabad Specialists Clinic
F-8 Markaz Islamabad
Tel:
 051-281-7244,
 051-281-7255
Fax:
 051-225-1212
Address:
Maroof International Hospital
10th Avenue, Markaz F-10, Islamabad
Tel:
 +92-51-2222920-40
Fax:
 +92-51-2222939
Email:
 post@profgill.com
Outcomes Of Cifn And Rbv Therapy For Chronic Hep C G3 Patients Who Relapsed With Previous Peg-Interferon And Riba Therapy
Uzma Adeeb1, Fatima Khatak1, Muzzaffar Gill1
1 Maroof international hospital F 10 markaz islamabad, F 10 markaz islamabad
Aims and objectives: There are no published studies about the efficacy of Consensus interferon and Riba combination in chronic hepatitis C(G3) relapsers wiith Peginterferon  Riba combination therapy. To evaluate the efficacy of consensus interferon and Ribavirin in patients previously treated with Pegylated interferon and Ribavirin combination therapy. We consecutively enrolled 20 patients with chronic hepatitis C G3 who relapsed with  previous treatment with Pegylated interferon for atleast 6 months.

Methods: The study was conducted between Feb 2009 to September 2009.

Inclusion criteria: chronic hepatitis C  G3 relapsers patients with documented history of  Pegylated interferon and Ribavirin therapy  for 6 months.

Exclusion criteria: active psychiatric history, platelet count < 75000, INR > 1.5,   S. Albumin < 2.5, portal vein diameter > 13mm on ultrasound and  active ischemic heart disease.
All enrolled patients have CBC, ALT, HCV PCR quantitative, HCV genotype,  thyroid function tests .and  blood sugar. .Patients  were given 15ug thrice weekly  consensus interferon and Ribavirin 400mg bid.The treatment duration was for 6 months. Patients were reviewed  4 weekly basis for clinical examination and CBC. We did check  HCV PCR quantitative @week 12.. The patients who had HCV PCR negative or 50% reduction in HCV PCR at week 12 were given further 3 months of therapy.

Results: Among 20 patients 15 were male and 5 were female. Median age was 45.Median viral load was 900,000 IU/ml .Sixteen out of 20 (80%) patients were HCVPCR negative @ week 12 of therapy. These 16 patients completed further 12 weeks of therapy and remained HCVPCR negative @end of total 24 weeks of therapy.Two patients required filgrastin to keep neutrophil count in normal range.

Conclusion: Consensus interferon (infergen ) Ribavirin combination is very optimistic option for HEP C G3 relapsers with Peg Interferon Riba combination.  Further studies are needed to confirm/refute these observation.. We   did give 6 months of therapy because of financial consideration.
News & Events
22.07.2010
Consensus interferon treatment for Pegylated interferon relapsers Hepatitis C patients rated the best study by Pakistan Society of Gastroenterology Annual conference in Bhurbun Muree May 30th 2010.
 
21.07.2010
Professor Gills team work will be presented in Barcelona , Spain in UEGW (United european gastroenterology week) October 23 to October 27th 2010
 
17.07.2010
Professor Gills team work will be presented in Barcelona , Spain in UEGW (United european gastroenterology week) October 23 to October 27th 2010
 
19.05.2010
World Hepatitis Day
 
08.04.2010
New directions in hepatitis c treatment.
 
08.04.2010
Treatment of hepatitis c revolutionized.
 
23.02.2010
Dr. Gill is invited to the 20th Conference of the APASL, to be held at the China National Convention Center, 25 to 28 March 2010, Beijing, China.
 
23.02.2010
Dr. Gill is invited to the International Liver CongressTM 2010 by EASL, taking place in Vienna, Austria, April 14 to 18, 2010.
 
17.02.2010
New treatment for hep c non responders and relapsers
 
08.01.2010
Treatment Challenges Of Hepatitis C Non Responders And Relapsers
 
21.08.2009
Invited lecture on Hepatitis B and C co-infection management on 8th annual international conference of Gastroenterology and Hepatology in Faisalabad 25-26th july 2009
 
22.06.2009
State of the art lecture on management of chronic hepatitis B, PSSLD single topic conference in Rawalpindi.